-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (glucagon + insulin human) in Hypoglycemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (glucagon + insulin human) in Hypoglycemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (glucagon + insulin human) in Hypoglycemia Drug Details: ABV-100...
-
Company Insights
Innovation and Patenting activity of Vaxart Inc Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Vaxart Inc Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
Hematology Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Hematology Pipeline Market Report Overview Hematology tests evaluate numerous conditions involving blood and its components and the tests that generate results immediately and can be done in a limited resource setting. The hematology pipeline market research report provides comprehensive information about the hematology pipeline reconstruction with a comparative analysis of the reconstruction at various stages of development and information about the clinical trials which are in progress. Key Segments ·      Immunohematology ·      Hematology Reagents ·      Hemostasis Calibrators and Controls ·      ...
-
Company Profile
Vaxart Inc – Company Profile
Vaxart Inc (Vaxart), formerly Aviragen Therapeutics Inc, is a clinical-stage pharmaceutical company that develops oral recombinant vaccines based on its proprietary oral vaccine platform, using state-of-the-art recombinant technology. The platform enables the company to develop oral versions of currently available vaccines, and design recombinant vaccines for new indications. The company is developing prophylactic vaccine candidates for a range of infectious diseases, including norovirus infection, seasonal influenza, respiratory syncytial virus (RSV) infection, and coronavirus (COVID-19) disease. It is also developing a...
Add to Basket -
Product Insights
Cervical Intraepithelial Neoplasia (CIN) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Cervical Intraepithelial Neoplasia Pipeline Drugs Market Overview Cervical Intraepithelial Neoplasia (CIN), also known as cervical dysplasia is characterized by abnormal appearance of cells on the surface of the cervix. Cervical dysplasia usually occurs in women aging twenty five to thirty five. Most cases of cervical dysplasia are caused by human papilloma virus (HPV). Signs and symptoms include genital warts, abnormal bleeding, spotting after intercourse, vaginal discharge, and low back pain. The CIN pipeline drugs market research report provides comprehensive information...
-
Product Insights
Influenzavirus B Infections Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update
Influenzavirus B Infections Clinical Trials Market Report Overview The influenzavirus B infections clinical trial market research report provides an overview of the influenzavirus B infections clinical trials scenario. The report provides top-line data relating to the clinical trials on influenzavirus B infections. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points...
-
Sector Analysis
Coronavirus Disease 2019 (COVID-19) Analyst Consensus Sales Analysis and Forecast, H2 2022
COVID-19 Analyst Consensus Sales Report Overview Prophylactic COVID-19 vaccines are projected to generate total sales of $264 billion from 2021 to 2028. The number of COVID-19 drugs with forecast sales nearly tripled due to the massive mandatory vaccination campaigns led by the major markets, which caused rapid increases in COVID-19 vaccines. BioNTech/Pfizer’s Comirnaty, Moderna’s Spikevax, and Pfizer’s Paxlovid are the top three marketed drugs with the highest peak forecast sales. Comparing Q4 2020 and H2 2022 total COVID-19 forecast sales within...
-
Product Insights
Net Present Value Model: Coronavirus Disease 2019 (COVID-19) vaccines
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Coronavirus Disease 2019 (COVID-19) vaccines Drug...
-
Product Insights
Net Present Value Model: Norovirus [strains Norwalk GI.1 + Sydney GII.4] (bivalent) vaccine
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Norovirus [strains Norwalk GI.1 + Sydney...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Norovirus [strains Norwalk GI.1 + Sydney GII.4] (bivalent) vaccine
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry Norovirus [strains Norwalk GI.1 + Sydney GII.4] (bivalent) vaccine Drug Details The vaccine candidate...